Trial Profile
An Open-Label, Single Site Study Using [123I]β-CIT Single Photon Emission Tomography (SPECT) to Evaluate Dopamine Transporter Binding Following Treatment With IRX4204 in Early Parkinson's Disease Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 May 2016
Price :
$35
*
At a glance
- Drugs IRX 4204 (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors Io Therapeutics
- 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology
- 12 May 2015 New trial record